Search or
𝛼SK
𝛼SKbullish
Otsuka Holdings (4578 JP): Rexulti Drives 1Q25 Result; Label Expansion And Acquisition Augur Well
766 Views02 May 2025 22:04
Otsuka reports 12% revenue growth in 1Q25, driven by 35% growth in Rexulti revenue. Guidance reaffirmed. Label expansion of Rexulti in PTSD and Araris acquisition offer long-term growth potential.
What is covered in the Full Insight:
- Financial Highlights
- Strong Performance of Rexulti
- Acquisition of Araris Biotech
- 2025 Guidance and Challenges
- Strategic Initiatives for Future Growth
Boomeranged on Mon, 9 Jun 2025 13:02
Otsuka presented results from an interim analysis of Phase 3 study evaluating sibeprenlimab, for immunoglobulin A nephropathy (IgAN). The study, the largest Phase 3 IgAN trial conducted to date, showed safety profile of sibeprenlimab was favorable and consistent with previously reported data. Sibeprenlimab received Priority Review designation from FDA last month following its BLA filing in March.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Otsuka Holdings (4578 JP): Rexulti, Abilify Drive 2025 Guidance Upward, All Eyes on Sibeprenlimab06 Nov 2025
- Otsuka Holdings (4578 JP): Better-Than-Expected 1H Performance Leads 2025 Guidance Raise04 Aug 2025
- Otsuka Holdings (4578 JP): Soft Guidance for 2025; Reduction of Investment Units15 Feb 2025
- Otsuka Holdings (4578 JP): Guidance Revised Upward for 2024, Core 2 Products Show Strength10 Feb 2025
- Otsuka Holdings (4578 JP): Revenue and Profit Continue to Rise, Rexulti Remains Key08 Nov 2024
x